Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors
Two regiment are used: N.B. The two regiments will be reported separately
1. Mitomycin + Gemcitabine intrahepatic together with Capecitabine. This treatment can be
offered patients with solid tumors where all standard treatments have been used. The
patients are not allowed to have extrahepatic disease. The purpose of the treatment are
to prolonged life.
2. FOLFOX where oxaliplatin is given intrahepatic each second time. The treatment are only
for patients with colorectal cancer where cure is possible but resection straight ahead
is not possible. The patients are allowed to have their colorectal cancer in situ for
operation latter on. If the patients are KRAS Wild-type, cetuximab are added.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.
Finn O Larsen, M.D. , Ph.D
Denmark: Ethics Committee